The D2.B10 (DBA/2-congenic) Dmdmdx mouse (also referred to as DBA/2J-mdx or D2-mdx mice) may be a superior Duchenne muscular dystrophy model as it better recapitulates several of the human characteristics of DMD myopathology (lower hind limb muscle weight, fewer myofibers, increased fibrosis and fat accumulation, and muscle weakness) relative to strains with this mutant allele on other genetic backgrounds.
Our preclinical efficacy testing services offer scientific expertise and an array of target-based and phenotype-based outcome measures, both in vivo and at endpoint, for flexible study designs and assay development in mouse models of Muscular Dystrophy. See our full service platform.
IMR Colony, The Jackson Laboratory
Duchenne muscular dystrophy (DMD) is a progressive muscular disorder caused by an imbalance between muscle degeneration and regeneration resulting in muscle degeneration, necrosis, accumulation of fat and fibrosis, and insufficient regeneration/loss of myofibers. The genetic cause of DMD are mutations of the dystrophin muscular dystrophy gene (DMD) on the X chromosome. The Dmdmdx mutation in mice has a termination codon in exon 23 that is predicted to result in a truncated protein. Heterozygous females are viable and fertile with no gross phenotypic abnormalities. Homozygous females and hemizygous males are viable and fertile with myopathic features of DMD; although the myopathology is both less severe than the human disease course and variable by mouse strain genetic background.
The muscle pathology observed for C57BL/10ScSn-Dmdmdx mice (also referred to as C57BL/10-mdx ; Stock No. 001801) includes active fiber necrosis, cellular infiltration, a wide range of fiber sizes, and numerous centrally nucleated regenerating fibers. However, adult C57BL/10-mdx mice fail to exhibit several of the skeletal muscle characteristics of DMD (such as smaller number of myofibers, accumulation of fat and fibrosis, insufficient myofiber regeneration, and loss of muscle weight). In addition, the C57BL/10 inbred strain is shown to possess greater muscle satellite cell self-renewal ability/efficiency than that of the DBA/2 inbred strain which may increase muscle regeneration/attenuate muscular dystrophy phenotype for MD mutations maintained on the C57BL/10 genetic background. As such, The Jackson Laboratory Repository created this DBA/2J-congenic Dmdmdx mouse model, D2.B10-Dmdmdx/J (also referred to as DBA/2J-mdx or D2-mdx; Stock No. 013141).
These DBA/2J-mdx mice may be expected to have a phenotype similar to other Dmdmdx mouse models. That is, when compared to C57BL/10-mdx animals, DBA/2-congenic Dmdmdx mice exhibit additional DMD characteristics such as lower hind limb muscle weight, fewer myofibers, increased fibrosis and fat accumulation, and remarkable muscle weakness. The DBA/2-congenic Dmdmdx phenotype is attributed to diminished myofiber regeneration (rather than accelerated myofiber degeneration). Unlike C57BL/10-mdx mice, no increased incidence of spontaneous rhabdomyosarcoma-like tumors are reported for the DBA/2-congenic Dmdmdx model.
In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. This is the case for these DBA/2J-mdx mice (Stock No. 013141). It should be noted that the phenotype could vary from that originally described for C57BL/10-mdx (Stock No. 001801). We will modify the strain description if necessary as published results become available.
The spontaneous mutation "X chromosome-linked muscular dystrophy" (mdx) has as a C-to-T transition (resulting in a termination codon) at position 3185 within exon 23 of the dystrophin muscular dystrophy gene (Dmd) on the X chromosome. C57BL/10ScSn-Dmdmdx (C57BL/10-mdx) mice are available from The Jackson Laboratory as Stock No. 001801. In 2010, some C57BL/10-mdx mice were backcrossed to DBA/2J inbred mice (Stock No. 000671) for several generations using a marker-assisted, speed congenic approach to generate the D2.B10-congenic strain (also referred to as DBA/2J-mdx) as Stock No. 013141.
|Allele Name||X linked muscular dystrophy|
|Allele Synonym(s)||Dmdmdx; X linked muscular dystrophy|
|Gene Symbol and Name||Dmd, dystrophin, muscular dystrophy|
|Gene Synonym(s)||Duchenne muscular dystrophy; CMD3B; DXS164; DXS230; DXS239; DXS268; DXS272; X-linked muscular dystrophy; BMD; pke; pke; DXS142; DXS206; DXS270; mdx; DXS269; MRX85; dys; X-linked muscular dystrophy; pyruvate kinase expression; Dp427; Dp71; mdx|
|Strain of Origin||C57BL/10ScSn|
|Molecular Note||This mutation arose in 1981 in a C57BL/10ScSn colony at University of Leicester. A C-to-T transition in the CAA codon in exon 23 (ENSMUST00000114000 chrX:g.83803333C>T; c.2983C>T; p.Q995*), resulting in a termination codon in place of a glutamine codon. This mutation is predicted to produce a truncated protein.|
The Dmdmdx mutant allele is on the X chromosome. Mutant mice were bred to DBA/2J inbred mice (Stock No. 000671) for many generations using a marker-assisted, speed congenic approach to establish this congenic strain. When maintaining the live congenic colony, heterozygous or homozygous females may be bred with hemizygous males.
When using the D2.B10-Dmdmdx/J mouse strain in a publication, please cite the originating article(s) and include JAX stock #013141 in your Materials and Methods section.
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.
MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.
Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.